Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

117.21
-0.2000-0.17%
Post-market: 117.210.00000.00%18:00 EDT
Volume:11.18M
Turnover:1.32B
Market Cap:145.97B
PE:308.45
High:119.96
Open:117.00
Low:116.78
Close:117.41
Loading ...

European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention

Business Wire
·
24 Feb

Optimistic Buy Rating for Gilead Sciences Driven by Anticipated FDA Approval and Strategic Market Positioning

TIPRANKS
·
24 Feb

Gilead Sciences, Inc. (GILD): Among Renaissance Technologies Portfolio’s Top Stock Picks

Insider Monkey
·
24 Feb

Elon Musk's DOGE overdrive, Trump bashes Boeing, and supersonic planes: Business news roundup

Quartz
·
22 Feb

Bernstein Adjusts Gilead Sciences Price Target to $120 From $105

MT Newswires Live
·
22 Feb

Gilead Sciences: Buy Rating Backed by Strong Q4 Performance, Strategic Initiatives, and Promising Pipeline

TIPRANKS
·
21 Feb

Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other News

Zacks
·
19 Feb

Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
19 Feb

Gilead Sciences' (NASDAQ:GILD) Upcoming Dividend Will Be Larger Than Last Year's

Simply Wall St.
·
19 Feb

Gilead Sciences Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
19 Feb

Deutsche Bank upgrades Gilead on its HIV treatment franchise

Investing.com
·
19 Feb

Top Calls on Wall Street: Nvidia, Apple, Tesla, Meta, Dell, Snowflake, Moderna, and More

Tiger Newspress
·
18 Feb

BRIEF-U.S. FDA Accepts Gilead’S New Drug Applications For Twice-Yearly Lenacapavir For Hiv Prevention Under Priority Review

Reuters
·
18 Feb

Gilead Sciences Says New Drug Application for Lenacapavir to Prevent HIV Accepted by FDA

MT Newswires Live
·
18 Feb

Gilead Sciences Inc - FDA to Review Lenacapavir Nda Under Priority Review, Pdufa Date June 19, 2025

THOMSON REUTERS
·
18 Feb

U.S. FDA Accepts Gilead’s New Drug Applications for Twice-Yearly Lenacapavir for Hiv Prevention Under Priority Review

THOMSON REUTERS
·
18 Feb